PureTech Health News
Project: None
Mechanism: Karuna
Source: None
Project: None
Mechanism: Gelesis
Source: None

Appointments bring strong track records of leadership and experience in commercial launches and medical affairs

PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced, clinical-stage biopharmaceutical company, announced today that its affiliate, Gelesis, has appointed Harry Leider, MD, MBA, former Chief Medical Officer and Group Vice President of Walgreens, as Chief Medical Officer. Gelesis also announced the appointment of Paul Fonteyne, Chairman and former CEO of Boehringer Ingelheim USA, to the Board of Directors.

Project: None
Mechanism: Alivio
Source: None

PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced, clinical-stage biopharmaceutical company, announced today that its affiliate, Alivio Therapeutics, has been granted two key patents broadly covering its inflammation-targeting technology platform. 

Project: None
Mechanism: None
Source: None

PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced, clinical-stage biopharmaceutical company, announced today that Joep Muijrers, PhD, Chief Financial Officer at PureTech Health, will present at the Jefferies 2018 Global Healthcare Conference in New York City on Wednesday, 6 June, at 9:30AM EDT.

Project: None
Mechanism: None
Source: None

The Annual General Meeting of PureTech Health plc (LSE: PRTC) (“PureTech Health” or the “Company”), was held at 3.00 pm BST on Friday 18 May 2018. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. 

CONTINUE